header logo image


Page 7«..6789..2030..»

Archive for the ‘Preventative Medicine’ Category

Manhattan internist and cardiologist, Dr. William Priester collaborates with Castle Connolly Private Health Partners to create a new concierge medical…

Friday, May 20th, 2022

Reestablishing a strong doctor-patient relationship

During Dr. Priester's tenure as internist and cardiologist in New York, he has built enduring relationships with his patient base, many of whom have been loyal to him for several decades. As his practices continued to grow, so did the administrative demands of operating and maintaining a private practice.

Like many other private internal medicine physicians, Dr. Priester has found himself at a crossroads: either continue to practice high-volume medicine, seeing many patients a day, but spending a limited amount of time with each of them or let his practice evolve to deliver highly personalized, preventative care and a chance to empower his patients with greater education and information.

The Priester CCPHP Membership

The concierge (membership-based) model continues to be a rewarding experience for physicians and patients alike. The increased time and flexibility allow concierge physicians, like Dr. Priester, to schedule patients for an hour appointment, if desired.

I've always believed in the importance of the doctor-patient relationship," says Dr. Priester. "This concierge model will not only support that relationship, but allow it to go one step further, by allowing more time with each patient."

Concierge patients of Priester CCPHP receive a host of added amenities as Members, including 24/7 connectivity to Dr. Priester via a direct phone number and a customized telehealth app, same/next day appointments with limited to no wait times regardless of medical necessity, and a robust wellness program called the SENS Solution Wellness Program powered by CCPHP, which focuses on Sleep, Exercise, Nutrition, and Stress Management.

Through the partnership with CCPHP, Dr. Priester also has access to Castle Connolly's Top Doctor Network of nearly 60,000 top recognized physicians nationwide. Being a recognized Top Doctor himself, Dr. Priester can consult with and refer patients to top physicians of similar distinction.

About Dr. Priester

William D. Priester, MD is a board-certified internist and cardiologist serving the community of New York, NY. Dr. Priester earned his Doctor of Medicine from the University of Iowa and completed his internship and residency in internal medicine at Metropolitan Hospital in New York. He completed his fellowship in cardiology at Lenox Hill Hospital, where he continues as an Adjunct Attending Physician.

Learn more about Dr. Priester's concierge program, Priester CCPHP:

About CCPHP

Castle Connolly Private Health Partners (CCPHP) works with exceptional physicians to create and support concierge (membership-based) healthcare programs that enable the optimal practice environment and the physician-patient relationship. Members (patients) pay an affordable fee to take advantage of a wide array of enhancements for a more convenient, comprehensive, collaborative, and personalized approach to support health and wellbeing. For more information, go toccphp.net.

SOURCE Castle Connolly Private Health Partners, LLC

See the article here:
Manhattan internist and cardiologist, Dr. William Priester collaborates with Castle Connolly Private Health Partners to create a new concierge medical...

Read More...

Tips on avoiding mosquitos this summer – morethanthecurve.com

Friday, May 20th, 2022

Whether youre planning summer activities at home or abroad, it is important to think about ways to avoid seasonal mosquitos if you want to ensure your recreational activities remain enjoyable. Besides the itchy and painful bites mosquitos leave behind, they can carry diseases that are easily transmitted to humans.

While the bites and infections they spread can often be treated, the best course of action is to prevent the bites altogether. If you have control of the environment and can think ahead, there are several ways you can sidestep the pests.

A good place to start is to make sure you have screens to block mosquitos from coming indoors and to be sure to eliminate standing water, where they can lay eggs. When evaluating for standing water, dont forget to check flower pots, rain gutters, plastic furniture covers, and toys.

If you are out and about, wearing long pants and sleeves can help cover bare skin, which gives mosquitoes easy access. In areas of high mosquito concentrations, treating clothing with permethrin, an anti-parasite cream, adds additional protection. While there are a number of different topical products on the market that claim to repel mosquitos, the validity of these claims is not always the same across brands. When looking for safe and effective ways to prevent mosquito bites, there are some products that demonstrate both safety and efficacy.

DEET is most strongly recommended by the Centers for Disease Control and Prevention and the Environmental Protection Agency (EPA). Some recommended alternatives to DEET are Picaridin and IR3535. While there are many natural mosquito repelling products, unfortunately, most have not been shown to be effective. The exception to this is oil of lemon eucalyptus, which has an efficacy comparable to DEET.

To be sure the product you would like to use is appropriate, the EPA has a free search tool that allows you to find specific products that will repel mosquitos, ticks, or both. When evaluating products, use caution with treated wristbands. Even though these may contain mosquito-repelling agents, they dont provide a wide enough protection zone to provide adequate coverage for the whole body.

And if your plans include international travel, scheduling an appointment with your physician is important to discuss ways to avoid mosquitos, as well as to obtain preventative medications for mosquito-borne illnesses. While mosquitos are certainly an unpleasant addition to outdoor plans, taking steps to avoid them contributes to having a safe and healthy summer.

Jessica Mayer, DO Program Director Suburban Family Medicine ResidencyVice-Chair Family Medicine Department

Suburban Family Medicine at Norristown2705 DeKalb Street, Suite 202Norristown, PA 19401610-275-7240

Dr. Mayer sees patients of all ages and is dedicated to providing compassionate care for the whole person. She is board certified in Family Medicine and director of Suburban Family Medicine Residency program and vice-chair of Family Medicine Department at Suburban Community Hospital.

Dr. Mayer completed her medical education at the Philadelphia College of Osteopathic Medicine (Pennsylvania) in 2008, internship at Crozer-Chester Medical Center (Pennsylvania) in 2009, and Residency at Mercy Suburban Hospital in 2011.

See the article here:
Tips on avoiding mosquitos this summer - morethanthecurve.com

Read More...

Nanomedicine and HIV Therapeutics – AZoNano

Friday, May 20th, 2022

The human immunodeficiency virus (HIV) has remained a significant challenge for researchers as there is currently a lack of cure or vaccine for this disorder.

Image Credit:PENpics Studio/Shutterstock.com

While antiretrovirals have improved the types of therapy available for patients, the ineffective requirement of lifetime treatment, as well as the development of resistance, is a major hurdle. However, the emergence and growth of nanotechnology may be a promising solution for a higher level of effective treatment as well as prevention of both HIV and acquired immunodeficiency syndrome (AIDS).

HIV was first identified in 1983 as the causative agent that resulted in AIDS, which was first reported in 1981.

The progression of the virus and the associated disease has been reported to be a global pandemic as one of the global lead causes of mortality in adults. The World Health Organization (WHO) has estimated the number of people living with HIV in 2020 was approximately 37.7 million; this can be translated as 0.7% of the global population, with Africa comprising the highest prevalence compared to other continents.

This majorly infectious disease consists of a primary strain, HIV-1, that can be traced to the chimpanzee species. This virus is an enveloped retrovirus that consists of two copies of single-stranded RNA.

There are three distinct stages of HIV, which describe the progression of the virus, including acute HIV infection, chronic HIV infection, and AIDS.

These can be summarized as the multiplying of the HIV virus, including the initial rapid destruction of CD4 T lymphocytes within the host, causing flu-like symptoms. This can then progress into the second asymptomatic stage, where the virus continues to multiply at low levels; within this chronic stage, the infection can progress into AIDS in 10 years or longer without antiretroviral therapy.

The final stage of HIV consists of AIDS, which is the most severe stage of the infection and can be characterized as having a high level of damage to the immune system, where the body is unable to fight against opportunistic infections. A diagnosis of AIDS is made when HIV patients have a CD4 count of 200 cells/mm3.

HIV/AIDS treatments have focused on antiretroviral therapies, with early treatment being only effective to a certain extent; the first drug that was FDA approved was in 1987, and since, approximately 25 drugs have received approval.

The progression of research, which included the release of protease inhibitors as well as the emergence of triple-drug therapy within the mid-1990s was highly promising for the efficacy of HIV/AIDS treatment. Currently, the highest standard of HIV/AIDS treatment consists of highly active antiretroviral therapy, involving three or more drugs provided simultaneously.

With further research into disease prevention strategies, vaccines have been considered the most effective agent for fighting global infections, evidenced by efficient control over infectious diseases such as measles, mumps, and rubella.

The challenges that can be associated with this chronic disease consist of requiring patient compliance for lifetime treatment, which can be difficult to adhere to. A lack of adherence to treatment can increase the probability of treatment failure and increase the likelihood of developing resistant strains of the virus.

Another limitation includes poor aqueous drug solubility, as this can impact the availability of the drug within the body and result in ineffective treatment of HIV.

The advancement in nanotechnology and nanomedicine has provided a promising future for HIV/AIDS therapeutics.

With the advancement of nanomedicine, strategies have been explored to overcome current challenges associated with HIV treatment. This includes oral administration of antiretroviral drugs and improving the water solubility of drugs, such as through solid drug nanoparticles (SDN).

Research into SDN formulations has been produced through a freeze-drying approach, which has been predicted to provide a similar pharmacokinetic standard as a conventional anti-HIV drug. However, this nanomedicine formulation was theorized to allow patients to take a 50% lower dose while experiencing the same effect. This prediction was validated with in vivo experimentation.

The development of SDN formulations has enabled success in superseding conventional oral drug formulations, such asritonavir-boosted lopinavir, which utilizes 42% ethanol and 15% propylene glycol. The use of lopinavir SDN formulations can achieve the production of an effective oral drug without the inclusion of ethanol.

Additionally, the potential inclusion of nanomedicine within this field of therapeutics allows for low-cost production of effective drugs as well as a decrease in required doses for patients.

Other subsets of nanomedicine that can be used for HIV therapeutics include long-acting injectable formulations (LAI), which can provide a solution to patient issues associated with low adherence to lifetime treatments.

An example of a drug that has been re-formulated to carry a nanomedicine component includes the non-nucleoside reverse transcriptase inhibitor, rilpivirine, which has been available as an oral medication from 2011, before being nanoformulated as a LAI.

This LAI nanomedicine has been proven to be effective, with concentrations being detected in rats up to 2 months after subcutaneous and intramuscular administration as well as detected in dogs for up to 6 months after administration.

New research in this area has included the Herbert Wertheim College of Medicine(HWCOM), who have undertaken nanotechnology research into the delivery of anti-HIV drugs across the blood-brain barrier, aiding in targeting HIV reservoirs within the brain. This research has included the development of a revolutionary technique consisting of using tiny magneto-electric nanoparticles as drug carriers.

Nagesh Kolishetti, one of the studys corresponding authors, stated, This delivery system can reduce the viral load, the amount of virus present, which normally contributes to neurological problems.

This type of combination therapy with the nanoparticles could result in a highly effective treatment regimen for the HIV-infected population who are addicted to a substance of abuse.

This is significant as HIV can cause neurological problems and disorders such as dementia and memory loss, which can be further increased by substance abuse

The future of HIV therapeutics can be said to be greatly intertwined with nanomedicine, with research into the use of nanoformulations that attempt to overcome the challenges of current HIV treatments.

With reports from WHO stating that 73% of HIV patients are treated with antiretroviral therapy and 680,000 deaths in 2020, this field requires a revolutionary change to traditional medicine to provide better treatment and even preventative care for this chronic disease.

Curley, P., Liptrott, N. and Owen, A., 2018. Advances in nanomedicine drug delivery applications for HIV therapy.Future Science OA, 4(1), p.FSO230. Available at: 10.4155/fsoa-2017-0069

FIU News. 2022.Researchers advance the use of nanoparticles to deliver HIV/AIDS drugs to the brain. [online] Available at: https://news.fiu.edu/2021/fiu-researchers-advance-the-use-of-nanoparticles-to-deliver-hivaids-drugs-to-the-brain

Hivinfo.nih.gov. 2022.The Stages of HIV Infection | NIH. [online] Available at:https://hivinfo.nih.gov/understanding-hiv/fact-sheets/stages-hiv-infection

Mamo, T., Moseman, E., Kolishetti, N., Salvador-Morales, C., Shi, J., Kuritzkes, D., Langer, R., Andrian, U. and Farokhzad, O., 2010. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.Nanomedicine, 5(2), pp.269-285. Available at: 10.2217/nnm.10.1

Worldpopulationreview.com. 2022.HIV Rates by Country 2022. [online] Available at: https://worldpopulationreview.com/country-rankings/hiv-rates-by-country

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

Read the rest here:
Nanomedicine and HIV Therapeutics - AZoNano

Read More...

The HIV Vaccine: What We Know, And What We Don’t – MadameNoire

Friday, May 20th, 2022

MadameNoire Featured Video

Source: Luke Dray / Getty

With all of the incredible medical advancements made, the HIV virus still escapes the grasp of the worlds top medical researchers and scientists, as the HIV vaccine is still in the works. The medical community managed to find a number of successful COVID-19 vaccine within a year of the viruss existence. Meanwhile, its been forty years since the first reports of people dying from a pneumonia-like virus. That virus was HIV.

Historically, HIV has plagued the Black community at a much higher rate than other races, says the CDC, tragically robbing millions of Black people of full lives, and leaving their loved ones with inconsolable heartbreak. There are a number of reasons for this, including a pervasive lack of access to health care such as preventative drugs and prophylaxis. The CDC also reports that Black people are at a biological disadvantage as theyve been shown to have lower levels of viral suppression against HIV.

Now, with Moderna launching clinical trials for a vaccine, theres new hope of conquering this disease that has taken the lives of 36.3 million people. Heres what we know about the HIV vaccine to date.

Source: BSIP / Getty

To date, there is no approved vaccine for HIV. Its estimated that over 100 HIV vaccines have been tested around the world since the virus was first discovered. However, to date, the only proven method for fighting HIV is antiviral treatments that can reduce the chances of death in individuals who are already infected with the virus. These drugs can be used to prevent the spread of HIV in three ways, says the National Library of Medicine. When taken daily, they can reduce the chances of transmission before exposure as well as after exposure. They can additionally be taken by infected individuals to prolong their lifespan.

Source: gilaxia / Getty

In 2021, Johnson & Johnson conducted what was known as the Imbokodo trials in sub-Saharan Africa. The company enlisted 2,600 women to participate in the trials and receive the vaccine. The vaccine was based on something called mosaic immunogens, says the National Institute of Health, which induce an immune response. Johnson & Johnson had hoped to see at least a fifty percent reduction rate of infection following the vaccine, but only saw a 25 percent reduction and canceled the trials in late 2021.

Source: Ignatiev / Getty

Medical researchers have been fascinated by two individuals who have evidently beat back the virus, without any medical assistance, says Science News. Analysts looked at over 1.5 billion cells from a patient known as EC2 and found zero functional copies of HIV in them. The patient did show nonfunctional copies of HIV, but those do not pose a known threat. These numbers were found after the patient had been infected for a long period of time, so experts believe the chances that the active virus is still simply hiding in the body are low. Another patient had active copies of HIV, but they had landed in a very specific gene that prevented them from spreading. Doctors describe the gene as being Wrapped in the molecular equivalent of razor wire. The immune systems of these two individuals are still being studied and could provide the blueprint for a future vaccine.

Source: Douglas Sacha / Getty

As of 2022, the National Institute of Allergy and Infectious Diseases in collaboration with Moderna has started early trials of three HIV vaccines that are of the same nature as the successful COVID-19 one an mRNA vaccine. The National Institute of Health explains that an mRNA vaccine works by Delivering a piece of genetic material that instructs the body to make a protein fragment of a target pathogen (such as a virus), which the immune system recognizes and remembers, so it can mount a substantial response if later exposed to that pathogen. This is the first study to examine an mRNA vaccine for the prevention of HIV. Participants in the trial will be evaluated at two and six months after injection, at which time samples from their blood and lymph nodes will be assessed. Its important to note that this HIV vaccine cannot cause infection.

RELATED CONTENT:Scientists May Have Successfully Cured HIV In The First Female Patient

See more here:
The HIV Vaccine: What We Know, And What We Don't - MadameNoire

Read More...

Experts warn of health effects from dusty conditions as sandstorm blankets UAE – Al Arabiya English

Friday, May 20th, 2022

Experts across the UAE have warned of the health impacts from the dusty conditions caused by sandstorms which have blanketed large parts of the country this week.

This week, forecasters issued a countrywide alert of hazardous weather due to sandstorm-related dust conditions.

For all the latest headlines follow our Google News channel online or via the app.

In recent days, the dusty weather has descended over almost all of the UAE.

As winds blow dust and sand into the atmosphere - affecting not only visibility - it also acerbates existing health conditions among residents, say doctors.

Dr Rakesh Kumar Gupta, deputy medical director and specialist pulmonologist of Lifecare Hospital, Musaffah, told Al Arabiya English: In this dusty weather, a higher number of patients seek medical attention for respiratory issues.

Exposure to sandstorms can cause health problems in people in the high-risk category like patients with pre-existing respiratory conditions, pregnant women, children, the elderly, and those who work outdoors.

While the larger dust particles can irritate the eyes, nose and throat, the finer particles can irritate the lungs and lead to allergic reactions.

Sandstorm exposure may worsen conditions like chronic obstructive pulmonary disease, asthma, and cardiovascular diseases. It may also trigger an acute attack of asthma in previously stable asthmatics, so these patients must take extra care.

The doctor said is necessary to take adequate precautions during a sandstorm.

Avoid going outside, especially when there is low visibility and high winds. Carry water with you to stay hydrated. Keep your mouth and nose covered with a mask or respirator. Wear protective eyewear and rinse your eyes with water if your eyes are irritated.

People with bad allergies can continue taking prescribed medications like antihistamines. If you experience symptoms like coughing, wheezing, breathing difficulty, chest pain or chest discomfort, seek medical help immediately.

Dr Muhammed Aslam, a specialist in pulmonology at the International Modern Hospital in Dubai, told Al Arabiya English that sandstorms can be detrimental to peoples health.

Nowadays we are seeing a lot of sandstorm episodes in the country; this is harmful to our health.

It affects our lungs, our respiratory system, our nose, our eyes. Also, those who already have allergies such as asthma are more prone to develop more systems such as runny nose, sneezing, throat discomfort, coughing and difficulty breathing, wheezing, and chest tightness.

It happens because of dust particles, while other virus particles can also be spread due to the sandstorm.

So the preventative measures is to stay indoors dont go outside if the sandstorm is heavy and watch the local weather forecast so you can monitor your activities.

Also, use air conditioning so that outside air will not come inside, and use allergy medicine if you are already allergies. You may need to up the dosage of your medicines as well but consult your doctor before doing so.

Ahmed El Mansoury, a consultant in pulmonology at NMC Royal Hospital in Sharjah, also said sandstorms can cause an increase in respiratory problems such as asthma and some infectious diseases such as pneumonia due to circulated dust particles, causing wheezing and coughing,

The best precaution is to stay at home; if you have to go outside then wear a mask or some protective device like you see with COVID-19 such as protection of eyes and hand washing and normal other precautions for respiratory illnesses.

Forecasters at the National Center of Meteorology said much of the same weather is expected over the course of the next few days, with a high likelihood of dust and sand affecting visibility up until at least Sunday.

A sandstorm has also engulfed Saudi Arabias capital and other regions of the Kingdom this week, hampering visibility and slowing road traffic.

Read more:

Sandstorm blankets Saudi Arabias capital Riyadh

Iraq sandstorm sends more than 1,000 to hospital

Originally posted here:
Experts warn of health effects from dusty conditions as sandstorm blankets UAE - Al Arabiya English

Read More...

What we know (and don’t know) about North Korea’s COVID-19 outbreak – WCVB Boston

Friday, May 20th, 2022

North Korea's first-reported COVID-19 outbreak is the "greatest turmoil" to befall the country since its founding more than 70 years ago, according to its leader Kim Jong Un, as the isolated and impoverished nation scrambles to curb the spread of a highly transmissible virus that risks causing a major humanitarian crisis.North Korea reported 21 more deaths and 174,440 new "fever cases" Friday, according to state media KCNA, though it did not specify how many of the deaths and cases were linked to COVID, likely due to the country's extremely limited testing capacity.The climbing death toll and surging "fever cases" come after North Korea said Thursday it had identified its first ever case of COVID-19 an alarming development for a country with one of the world's most fragile public health systems and a largely unvaccinated population.But given the opaque nature of the regime and the country's isolation from the world a trend that has only exacerbated since the pandemic it is extremely difficult to assess the real situation on the ground.Foreign diplomats and aid workers had fled North Korea en masse in 2021 due to shortages of goods and "unprecedented" restrictions on daily life, making it all the more impossible to obtain information from the country other than through official state media.But North Korean state media reports have been vague, and many important questions remain unanswered, including the country's vaccine coverage and the lockdown's impact on the livelihood of its 25 million people.Here is what we know, and what we don't know about the outbreak:How did the outbreak emerge?North Korean authorities have not announced the cause of the outbreak.North Korea's borders have been tightly sealed since January 2020 to keep the virus at bay, making the so-called "hermit nation" even more isolated from the world. It even declined invitations to send teams to compete at the Tokyo and Beijing Olympics, citing the threat of COVID-19.And as new variants began to emerge, it stepped-up those efforts, cutting off nearly all trade with China the country's biggest trading partner and economic lifeline for the Kim regime with imports from Beijing dropping 99% from September to October 2020.It remains unclear how the virus slipped through the country's tightly-sealed borders.When KCNA reported on the first identification of COVID-19 in the country on Thursday, it did not even specify how many infections had been defected. It simply said samples collected from a group of people experiencing fevers on May 8 had tested positive for the highly contagious omicron variant.By Friday, KCNA was reporting that 18,000 new "fever cases" and six deaths were recorded on Thursday, including one who tested positive for the BA.2 sub-variant of omicron."A fever whose cause couldn't be identified explosively spread nationwide since late April," the newspaper said. "As of now up to 187,800 people are being isolated."On Saturday, KCNA said a total of 524,440 people had reported "fever" symptoms between late April and May 13. Among them, 280,810 people were still being treated in quarantine, while the rest had recovered.Can North Korea cope with a large-scale outbreak?An outbreak of COVID-19 could prove disastrous for North Korea. The country's dilapidated health care infrastructure and lack of testing equipment is unlikely to be up to the task of treating a large number of patients with a highly infectious disease.North Korea's lack of transparency and unwillingness to share information also poses a challenge.North Korea has never formally acknowledged how many died during a devastating famine in the 1990s that experts suggest killed as many as 2 million. Those who fled the country at the time shared horrific stories of death and survival, and a country in chaos."North Korea has such a limited supply of basic medicine that public health officials need to focus on preventative medicine. They would be ill-equipped to deal with any kind of epidemic," Jean Lee, director off the Hyundai Motor-Korea Foundation Center for Korean History at the Washington-based Woodrow Wilson Center, told CNN at the outset of the pandemic.Doctors who have defected in recent years often speak of poor working conditions and shortages of everything from medicine to basic healthcare supplies.Choi Jung-hun, a former physician in North Korea who fled the country in 2011, said when he was helping to combat a measles outbreak in 2006 to 2007, North Korea did not have the resources to operate round-the-clock quarantine and isolation facilities.He recalled that after identifying suspicious cases, manuals for doctors said patients were supposed to be transferred to a hospital or a quarantine facility for monitoring."The problem in North Korea is that manuals are not followed. When there wasn't enough food provided for the people at hospitals and quarantine facilities, people escaped to look for food," Choi said during an interview with CNN in 2020.How is North Korea responding so far?North Korean state media declared the situation a "major national emergency" upon admitting the first officially reported COVID infection.On Thursday, Kim placed all cities into lockdown and ordered "people with fever or abnormal symptoms" into quarantine; he also directed the distribution of medical supplies the government had reportedly stocked in case of a COVID emergency, according to KCNA.Kim later chaired a meeting of the country's powerful politburo, which agreed to implement "maximum" emergency anti-epidemic measures. The measures include isolating work units and pro-actively conducting medical checkups to find and isolate people with "fever and abnormal symptoms," the KCNA reported Friday."Practical measures are being taken to keep the production going at a high rate in the major sectors of the national economy and to stabilize the life of the people to the maximum," KCNA said.According to KCNA, the politburo criticized the country's anti-epidemic sector for "carelessness, laxity, irresponsibility and incompetence," saying it "failed to respond sensitively" to increasing COVID-19 cases across the world, including in neighboring regions.A reporter for Chinese state media CGTN released a rare video from Pyongyang on Friday, recounting his experience on the ground."As far as we know, not many people in Pyongyang have been vaccinated, and the medical and epidemic prevention facilities are in short supply," reporter Zang Qing said in a Weibo post."Because the capital is in lockdown, the food I have at home is only enough for a week. We are still awaiting what policy the government will announce next."At a meeting Saturday, Kim inspected the country's emergency epidemic measures and medical supplies. He also urged North Korean officials to learn from China's "advanced and rich quarantine results and experience they have already achieved in their fight against the malicious infectious disease," according to KCNA.What about North Korea's vaccine coverage?North Korea is not known to have imported any coronavirus vaccines despite being eligible for the global COVID-19 vaccine sharing program, Covax.Assuming most North Koreans are unvaccinated, an outbreak in the country which has limited testing capabilities, inadequate medical infrastructure and which has isolated itself from the outside world could quickly become deadly.Calls are mounting on the country's leadership to provide access to vaccines."There is no evidence to show that North Korea has access to enough vaccines to protect its population from COVID-19. Yet, it has rejected millions of doses of AstraZeneca and Sinovac vaccines offered by the WHO-led Covax program," said Amnesty International's East Asia researcher Boram Jang, in a statement."With the first official news of a COVID-19 outbreak in the country, continuing on this path could cost many lives and would be an unconscionable dereliction of upholding the right to health."In February, Covax reportedly scaled back the number of doses allocated to North Korea because the country failed to arrange for any shipments, according to Reuters.A spokesperson for Gavi, the Vaccine Alliance, said Covax has moved to "needs-based vaccine allocations" and "has currently not committed any volume" for North Korea."In case the country decides to start a COVID-19 immunization program, vaccines could be made available based on criteria of Covax objectives and technical considerations to enable the country to catch up with international immunization targets," the spokesperson said.

North Korea's first-reported COVID-19 outbreak is the "greatest turmoil" to befall the country since its founding more than 70 years ago, according to its leader Kim Jong Un, as the isolated and impoverished nation scrambles to curb the spread of a highly transmissible virus that risks causing a major humanitarian crisis.

North Korea reported 21 more deaths and 174,440 new "fever cases" Friday, according to state media KCNA, though it did not specify how many of the deaths and cases were linked to COVID, likely due to the country's extremely limited testing capacity.

The climbing death toll and surging "fever cases" come after North Korea said Thursday it had identified its first ever case of COVID-19 an alarming development for a country with one of the world's most fragile public health systems and a largely unvaccinated population.

But given the opaque nature of the regime and the country's isolation from the world a trend that has only exacerbated since the pandemic it is extremely difficult to assess the real situation on the ground.

Foreign diplomats and aid workers had fled North Korea en masse in 2021 due to shortages of goods and "unprecedented" restrictions on daily life, making it all the more impossible to obtain information from the country other than through official state media.

But North Korean state media reports have been vague, and many important questions remain unanswered, including the country's vaccine coverage and the lockdown's impact on the livelihood of its 25 million people.

Here is what we know, and what we don't know about the outbreak:

North Korean authorities have not announced the cause of the outbreak.

North Korea's borders have been tightly sealed since January 2020 to keep the virus at bay, making the so-called "hermit nation" even more isolated from the world. It even declined invitations to send teams to compete at the Tokyo and Beijing Olympics, citing the threat of COVID-19.

And as new variants began to emerge, it stepped-up those efforts, cutting off nearly all trade with China the country's biggest trading partner and economic lifeline for the Kim regime with imports from Beijing dropping 99% from September to October 2020.

It remains unclear how the virus slipped through the country's tightly-sealed borders.

When KCNA reported on the first identification of COVID-19 in the country on Thursday, it did not even specify how many infections had been defected. It simply said samples collected from a group of people experiencing fevers on May 8 had tested positive for the highly contagious omicron variant.

By Friday, KCNA was reporting that 18,000 new "fever cases" and six deaths were recorded on Thursday, including one who tested positive for the BA.2 sub-variant of omicron.

"A fever whose cause couldn't be identified explosively spread nationwide since late April," the newspaper said. "As of now up to 187,800 people are being isolated."

On Saturday, KCNA said a total of 524,440 people had reported "fever" symptoms between late April and May 13. Among them, 280,810 people were still being treated in quarantine, while the rest had recovered.

An outbreak of COVID-19 could prove disastrous for North Korea. The country's dilapidated health care infrastructure and lack of testing equipment is unlikely to be up to the task of treating a large number of patients with a highly infectious disease.

North Korea's lack of transparency and unwillingness to share information also poses a challenge.

North Korea has never formally acknowledged how many died during a devastating famine in the 1990s that experts suggest killed as many as 2 million. Those who fled the country at the time shared horrific stories of death and survival, and a country in chaos.

"North Korea has such a limited supply of basic medicine that public health officials need to focus on preventative medicine. They would be ill-equipped to deal with any kind of epidemic," Jean Lee, director off the Hyundai Motor-Korea Foundation Center for Korean History at the Washington-based Woodrow Wilson Center, told CNN at the outset of the pandemic.

Doctors who have defected in recent years often speak of poor working conditions and shortages of everything from medicine to basic healthcare supplies.

Choi Jung-hun, a former physician in North Korea who fled the country in 2011, said when he was helping to combat a measles outbreak in 2006 to 2007, North Korea did not have the resources to operate round-the-clock quarantine and isolation facilities.

He recalled that after identifying suspicious cases, manuals for doctors said patients were supposed to be transferred to a hospital or a quarantine facility for monitoring.

"The problem in North Korea is that manuals are not followed. When there wasn't enough food provided for the people at hospitals and quarantine facilities, people escaped to look for food," Choi said during an interview with CNN in 2020.

North Korean state media declared the situation a "major national emergency" upon admitting the first officially reported COVID infection.

On Thursday, Kim placed all cities into lockdown and ordered "people with fever or abnormal symptoms" into quarantine; he also directed the distribution of medical supplies the government had reportedly stocked in case of a COVID emergency, according to KCNA.

Kim later chaired a meeting of the country's powerful politburo, which agreed to implement "maximum" emergency anti-epidemic measures. The measures include isolating work units and pro-actively conducting medical checkups to find and isolate people with "fever and abnormal symptoms," the KCNA reported Friday.

"Practical measures are being taken to keep the production going at a high rate in the major sectors of the national economy and to stabilize the life of the people to the maximum," KCNA said.

According to KCNA, the politburo criticized the country's anti-epidemic sector for "carelessness, laxity, irresponsibility and incompetence," saying it "failed to respond sensitively" to increasing COVID-19 cases across the world, including in neighboring regions.

A reporter for Chinese state media CGTN released a rare video from Pyongyang on Friday, recounting his experience on the ground.

"As far as we know, not many people in Pyongyang have been vaccinated, and the medical and epidemic prevention facilities are in short supply," reporter Zang Qing said in a Weibo post.

"Because the capital is in lockdown, the food I have at home is only enough for a week. We are still awaiting what policy the government will announce next."

At a meeting Saturday, Kim inspected the country's emergency epidemic measures and medical supplies. He also urged North Korean officials to learn from China's "advanced and rich quarantine results and experience they have already achieved in their fight against the malicious infectious disease," according to KCNA.

North Korea is not known to have imported any coronavirus vaccines despite being eligible for the global COVID-19 vaccine sharing program, Covax.

Assuming most North Koreans are unvaccinated, an outbreak in the country which has limited testing capabilities, inadequate medical infrastructure and which has isolated itself from the outside world could quickly become deadly.

Calls are mounting on the country's leadership to provide access to vaccines.

"There is no evidence to show that North Korea has access to enough vaccines to protect its population from COVID-19. Yet, it has rejected millions of doses of AstraZeneca and Sinovac vaccines offered by the WHO-led Covax program," said Amnesty International's East Asia researcher Boram Jang, in a statement.

"With the first official news of a COVID-19 outbreak in the country, continuing on this path could cost many lives and would be an unconscionable dereliction of upholding the right to health."

In February, Covax reportedly scaled back the number of doses allocated to North Korea because the country failed to arrange for any shipments, according to Reuters.

A spokesperson for Gavi, the Vaccine Alliance, said Covax has moved to "needs-based vaccine allocations" and "has currently not committed any volume" for North Korea.

"In case the country decides to start a COVID-19 immunization program, vaccines could be made available based on criteria of Covax objectives and technical considerations to enable the country to catch up with international immunization targets," the spokesperson said.

Read more from the original source:
What we know (and don't know) about North Korea's COVID-19 outbreak - WCVB Boston

Read More...

Statin therapy: Does the gut microbiome affect outcomes? – Medical News Today

Friday, May 20th, 2022

Between 25% and 30% of older adults in theUnited StatesandEuropetake statins to treat or prevent atherosclerosis cardiovascular disease (ACVD) the buildup of cholesterol plaque in artery walls that stops blood flow.

Although effective in decreasing ACVD-related deaths, their effects differ between people. While pharmacological and genetic factors are known to contribute to statin response, personalized approaches remain limited.

Recentstudieshave suggested a link between the gut microbiome and statin use and the gut microbiome andACVD risk. Otherstudieshave found that gut bacteria metabolize statins into secondary compounds.

Knowing whether and how gut microbiome composition affects peoples response to statins could help researchers and clinicians personalize statin-based treatments.

In a recent study, researchers investigated whether and how the gut microbiome composition affects a persons response to statins and metabolic health.

They found that differences in gut microbiome composition influenced peoples response to statins as well as metabolic health parameters, including insulin resistance and blood glucose levels.

The authors present very compelling work linking the microbiome with the efficacy and toxicity of statin medications,Dr. Sony Tuteja, Research Assistant Professor of Medicine at the University of Pennsylvania, not involved in the study, toldMedical News Today.

This adds to the already large amount of work pointing to the microbiome in explaining the variation in drug response that cannot be explained by host genetics, she added.

The new study was published in the journalMed.

For the study, the researchers built statistical models with data from 1,848 participants from the Arivale cohort study.

Data included microbiome composition from stool samples and plasma metabolite levels from blood samples. The researchers also made use of genomics and demographics data.

They also used data from 991 individuals from the European MetaCardis cohort to validate their model.

Statins work byinhibitinga rate-limiting enzyme involved in cholesterol synthesis, known as HMG-CoA reductase.

The researchers first sought to see whether HMG levels could be linked with statin use. They found that HMG levels positively correlate with statin use and inversely correlate with LDL cholesterol.

This, they wrote, means that HMG levels may indicate the extent to which statins inhibit their target enzyme. So, they used levels of HMG in the blood to represent statin use.

In their analysis, the researchers found that people with more diverse microbiomes exhibited lower HMG levels, indicating a decreased statin response.

Further analysis showed that individuals with a Bacteroides-dominated gut microbiome had the strongest on-target effects including high plasma HMG and low LDL cholesterol levels.

However, they also had the greatest metabolic disruption as measured by glucose levels and insulin resistance.

Meanwhile, people with Ruminococcaceae-dominated gut microbiomes demonstrated a clear LDL-lowering response without metabolic disruption.

The researchers suggest that this microbiome composition type may thus benefit from statin therapy without metabolic complications.

To explain the results, the researchers noted that Rum. bacteria is enriched in bacterial species that may serve as a buffer against off-target metabolic effects.

They also note that bacterial species in Rum. microbiomes metabolize statins and other prescription drugs at a lower rate than other microbiome compositions, which may explain their resistance to metabolic issues from statin use.

By contrast, Bacteriodes bacteria metabolize statins, potentially explaining the metabolic effects of statin use in Bacteriodes-dominated microbiomes.

Adding to this,Dr. Sean Gibbons, Washington Research Foundation Distinguished Investigator and Assistant Professor at the Institute for Systems Biology, one of the studys authors, told MNT:

We also saw an association between statin responses and mucus degrading genes in the metagenomes i.e. greater mucus degradation capacity was associated with more intense statin responses, which is in line with arecent preprint.

Finally, there is evidence that bacterial bile acid metabolism influences cholesterol levels in the body, with a recentstudyshowing how certain secondary bile acids produced by microbes were associated with lowering LDL cholesterol in blood, he added.

Dr. Tuteja also noted: Microbially derived metabolites, such as bile acids, may be competing with host drug uptake transporters which will limit the amount of statin medication reaching the liver.

Statins alter the microbiome composition and, in particular, those bacteria with the ability to metabolize bile acids, altering the bile acid pool, which impacts cholesterol biosynthesis, she continued.

Dr. Oluf Pedersen, professor of human metabolism at the University of Copenhagen, Denmark, added that the underlying molecular mechanisms remain unknown.

However, he noted that interindividual variation in statin response might arise as different microbiome compositions influence glucose and cholesterol synthesis by the liver differently.

The researchers concluded that microbiome composition influences peoples response to statins independently of genetic markers. They add that further research monitoring the gut microbiome may help inform precision statin treatment.

When asked about the studys limitations, Dr. Tuteja explained:

The major limitation is the cross-sectional design. Prospective, interventional studies will be required to determine the directionality of the effect.

The authors present data from two descriptive observational studies and cannot tell if there are any causal relationships. To address this, long-term intervention studies are needed, [including detailed analysis of the gut microbiome] before and after a period of statin intake [alongside] careful measurements of carbohydrate and lipid metabolism, added Dr. Pedersen.

Read the original here:
Statin therapy: Does the gut microbiome affect outcomes? - Medical News Today

Read More...

New Preventative Medicine Facility Wraps Work in NYC – Healthcare Construction and Operations News

Sunday, November 7th, 2021

By HCO Staff

NEW YORK CITYWare Malcomb, an award-winning international design firm, recently announced construction is complete on Princeton Longevity Center, a preventive medicine facility located at 1 World Trade Center. Ware Malcomb provided the interior architecture and design services for the project.

The 10,000-square-foot facility is a new build-out that includes a 2,000-square foot-imaging-diagnostic licensing suite, including advanced technology imaging rooms and a CT scan room. The space also includes a reception area, a lounge, individual patient rooms, exam rooms, offices, and a fitness room. The design is hospitality-focused and mirrors the aesthetic established at their Princeton, New Jersey location.

Princeton Longevity Center is extremely patient-centric in all of their decisions, said Marlyn Zucosky, Regional Director, Interior Architecture & Design for Ware Malcomb. We were pleased to work closely with them to design a facility to enhance their patients experience and wellness. The result is a highly-functional, relaxing and beautiful space in one of the worlds highest-profile buildings.

At the entrance to the suite, a virtual receptionist assists guests with check-in. The inviting lounge offers spectacular views from the 71st floor of the 1 World Trade Center and incorporates wood-look luxury vinyl tile flooring, as well as a curved reception desk with backlit features. A custom hand-woven rug, a unique light fixture and a custom millwork coffee bar add a hospitality vibe to the spacious waiting area.

Individual patient rooms provide guests with a private space while they spend the day at Princeton Longevity Center and include computers, showers and a relaxing lounge atmosphere. The exam rooms and doctor offices, which also provide views of the city, incorporate calming colors. The rich tones of the design color palette are a dramatic contrast to the natural light provided by floor-to-ceiling windows.

The general contractor was Icon Interiors, Inc. The project achieved LEED Gold certification, a requirement of all 1 World Trade Center tenants. This is Ware Malcombs second project for Princeton Longevity Center; the first was their Princeton, NJ location, completed four years ago. Princeton Longevity Center is a leader in the preventive medicine market, offering the most advanced technology services and serving C-suite clientele with comprehensive medical evaluations.

Here is the original post:
New Preventative Medicine Facility Wraps Work in NYC - Healthcare Construction and Operations News

Read More...

MPD working with faith-based leaders to fight violent crime – FOX13 Memphis

Sunday, November 7th, 2021

MEMPHIS, Tenn. Across Memphis, there have been at least 270 homicides compared to 263 at the same time last year. With less than two months left in the year, the city is on pace to shatter last years record.

In an effort to slow things down, MPD is working on getting to the source of violent crime.

Faith-based leaders have partnered with law enforcement to offer resources. The goal is for officers not just to respond to crimes but also to stop them before they start.

Preventative medicine is the best form of medicine, said Pastor Ricky Floyd with Pursuit of God Church.

To cure a city plagued by violent crime, the Memphis Police Department has partnered with faith-based leaders to get to the root of the problem.

Couples counseling, trauma response, gang talk, domestic violence, conflict resolution. Those are some of the things problematic in our community, said Memphis Deputy Police Chief PaulWright.

Faith-based leaders, MPD, and the U.S. Attorneys Office are hosting the Better Community Summit Saturday. The aim is to connect attendees with experts who specialize in areas Wright described.

Young people have seen things happen in their community now that they dont quite understand.If they dont get that fixed, it may be a problem in the future, Wright said.

Floyd said this summit is vital to lift the community.

Sometimes people think no one is out there to help me. Theres a lot of help available, said Floyd.

The summit isSaturday from 10 a.m. to 2 p.m.at Pursuit of God Transformation Center in Frayser.

CLICK HERE TO DOWNLOAD

Trending stories:

2021 Cox Media Group

Read more from the original source:
MPD working with faith-based leaders to fight violent crime - FOX13 Memphis

Read More...

Cornell grad and lecturer touts benefits of plant-based diet – ithaca.com

Sunday, November 7th, 2021

If there is one piece of advice that 87-year-old Dr. T. Colin Campbell would give to those looking to age well and stay healthier longer, it would be to change your diet to a plant based, whole food approach.

The idea of plant based eating has gained popularity in recent years, but it was first coined by Campbell back in 1978. The bestselling coauthor of The China Study (published in 2006) said it has been exciting to see it gain traction in the last several years.

Its interesting because the idea of a plant based diet possibly being the best and the way of the future is just beginning to take hold in the mainstream public, Campbell said.

His recommendation that most everyone can adopt a plant based diet and have it benefit their lives hinges on a discovery he made early in his career: that people do not need to eat animal protein in order for their bodies to get the protein they need.

For the son of a dairy farmer, this flew in the face of what he had believed growing up but the evidence that a plant based diet can prevent and, in the vast majority of cases, even reverse common American ailments like diabetes, high cholesterol and heart disease was so strong that he dedicated his career to researching it and publicly sharing his findings. He has also worked to shape public policy around health and nutrition and was the liaison to Congress for the medical research community in 1980 and 1981.

Campbell wasnt always interested in studying nutrition. He was completing his first year of veterinary school when he received a telegram from a well known Cornell Professor offering him a scholarship and research opportunity, which led him to complete his education at Cornell University and MIT in the field of nutrition, biochemistry and toxicology. During his time at Cornell, around 1965, he was tasked with coordinating an effort to aid malnourished children in the Philippines. It was believed at the time that the children needed more animal protein to be healthy, but what Campbell found instead was that the few children who came from families who were able to consume more animal protein had a higher rate of liver cancer than their peers.

I couldt quite believe what I was seeing, Campbell said. I had many students work in the lab on this question and over the years found that there is no need to consume animal food to get that protein. That is totally false.

Campbell spent a decade on the faculty of Virginia Techs Department of Biochemistry and Nutrition, then returned to Cornell in 1975, where he currently holds his endowed chair as a professor emeritus of nutritional biochemistry in the Division of Nutritional Sciences.

In recent years Campbell founded a non-profit organization on online learning in nutrition which recently developed, under the direction of Campbells daughter LeAnne Campbell, the program Plant Forward, which holds online workshops.

The workshops teach a simple philosophy that can be difficult to put into practice at first but pays great dividends if the individual can stick with it for a month or two, Campbell said.

The people who stay with it are often people who have a serious health problem or have a motivation, he said. Sometimes the effects are almost immediate.

People can see their blood sugar drop precipitously in one day, he said. Its amazing.

The key is to go all-in on the new diet. He likened it to quitting smoking just cutting down to one or two cigarettes per day or smoking on some days but not on others is not likely to lead to success in the longterm. But soon, Campbell said, this new kind of eating will become second nature and even enjoyable.

Youll all of a sudden discover you crave a salad, he said. Just eat vegetables, grains, nuts, and avocados for the oil and fat.

As much as possible, stay away from added oils and refined carbs, he added.

The effects of adopting a whole plant-based diet are striking, he said.

We can turn experimental liver cancer genes on with animal based protein and turn it off by eating a plant based diet, he said.

Campbells own father died of a heart attack when he was 70, and his wifes mother died of colon cancer when she was just 51. That motivated us to think about changing our diet, so we did, he said. His wife is 80 years old, and both are largely medication free other than a short period Campbell spent on medication to control his blood pressure.

Campbells first book, The China Study, came out of a partnership in the 1980s with researchers at Oxford University and the Chinese Academy of Preventative Medicine and sold nearly four million copies worldwide. Campbell followed that up with his second book, Whole, in 2013, which is focused on the science behind plant based eating.

In 2020 he published The Future of Nutrition: An Insiders Look at the Science, Why We Keep Getting it Wrong, and How to Start Getting It Right.

He still gives lectures and is involved with the online Plant-Based Nutrition Certificate in Partnership with eCornell. His research is the cornerstone of the 2011 documentary film Forks Over Knives, and his oldest son, Nelson Campbell, made another popular documentary on the topic called Plant Pure Nation.

Some advice that he received from his father that has guided him throughout his life: Tell the truth, the whole truth, and nothing but the truth. It is a philosophy that allowed him to question his original assumption that eating animals must be good for health.

The key is to be honest with yourself and check your own biases, he said. Thats really critical.

See original here:
Cornell grad and lecturer touts benefits of plant-based diet - ithaca.com

Read More...

Meet the Cork-born bread activist who has Goldie Hawn buying her loaves – Irish Examiner

Sunday, November 7th, 2021

Karen ODonoghue has a goal: to cure everyone in Ireland of IBS. And, paradoxically, shes aiming to use bread to do it.

Already you can see the bands of gastroenterologists around the country tut-tutting at such a tall order.

Yet, ODonoghue should know a thing or two. In 2018 she was named Gut Specialist of the Year in the UK and she is currently a judge for the World Bread Awards.

Actress Goldie Hawn rates her anti-inflammatory bread so highly that she took ten loaves with her back to the US and claimed it cured both her and her sons Irritable Bowel Syndrome (IBS).

Ears perk.

Every system and organ in the body is dependent on the health of the gut microbiome so when you nourish the microbiome, it automatically nourishes the brain, says ODonoghue from her new bakery in Mayo.

Youll make better decisions in your life, have more energy, and youll enjoy better sex, she adds, with a twinkle.

Eyebrows raise.

Bread activism it kind of has a ring to it.

And this is the business ODonoghue is in, swapping prescriptive medicine for a food-led approach to managing and healing ones own body.

As the founder of the Happy Tummy Company in London in 2014, she is responsible for single-handedly pioneering a scientifically-developed range of breads aimed at alleviating IBS (her UK customers coined the term magic poo bread for how much it helped them), mental health issues, period and menopause pain, and, what she describes as functional rehab for both physical injury and trauma from illness.

The Happy Tummy Company was born out of a deep desire to help others, and in turn, out of illness.

Growing up in Cork where her parents ran a horticulture company, when ODonoghue was 10 years old her mother was diagnosed with cancer.

She vividly remembers the lightning bolt moment that would dictate the course of her future.

Growing up with a mother who had cancer and who ultimately died from it, I was very aware of the part food had to play in our overall wellbeing.

During the time of my mums cancer treatments I remember digging the soil with my dad, planting beech saplings, and I had this epiphany: when Im older Im going to create a brand thats all about food as preventative medicine.

Fast forward to 24-year-old Karen living in London.

Having spent most of her life battling with IBS, she found herself depressed and anxious.

The older I got and the more my IBS became an issue, I knew I needed to go back to that ambition I had as a little girl. Intuitively I always knew that food is medicine.

She started poring over scientific research papers to learn about the gut microbiome and discovered that our gut bacteria works to a specific mathematical equation: we should be eating 66% dietary fibre to 33% dietary protein and five grams of prebiotic fibre every day.

Based on this, she created her own formula (her father was a maths teacher they regularly discussed theorems at the dinner table) and applied it to the bread making process.

It was during this time that she discovered a gluten-free grain from Africa.

The star ingredient is teff, grown in Ethiopias highlands, which is high in protein, calcium and iron, along with prebiotic fibres and antioxidants, all of which stimulate the growth of good gut bacteria, reduce inflammation and nourish the lungs, brain, skin, and nervous system. Teff relieves bloating and constipation and also helps to balance hormone levels, stimulate digestion and strengthen bones.

After 18 months of a mad scientist-like existence in her London flat she developed a loaf of bread that would completely rid her of her IBS.

From having one bowel movement every three weeks, within a week she was doing two poos a day.

The shape of her tummy changed, her depression and anxiety disappeared and she started to feel alive again.

That loaf is now her best-selling Chia Teff Loaf, aka the magic poo bread

In 2014 she established her London bakery, The Happy Tummy Company (cue Goldie Hawn and many more high-profile followers) in Hackney and a school where she taught students how to use food both as preventative and prescriptive medicine.

The bread-making process started as a means to cure her own IBS but once the word got out, loaves were flying off the shelves like IBS-crusading hotcakes.

Last year, after 13 years in the UK, she decided to relocate the business headquarters to Westport in Mayo.

ODonoghue walks the talk. She beams of health and is genuinely positive, which is infectious to be around.

ODonoghue believes we need to pare back how we look at bread and start viewing our consumption of it primarily from a health perspective, and flavour as a secondary issue.

The reason bread has a branding problem, she believes, is because bakers are obsessed with the aesthetics of what they are making over nourishment, creating white, fluffy sourdough breads using commercial wheat.

Consumers, particularly those who have issues with gluten or coeliac disease, eat these breads and all of a sudden feel bloated, lethargic, and agitated. And thats not surprising.

You are eating a wheat that is not very natural.

The Chia Teff Loaf takes about three days to make and is packed with organic teff (so no herbicides or pesticides), sprouted buckwheat, walnuts, Brazil nuts, almonds, linseed, and chia seeds all expensive ingredients.

It costs 25 per loaf.

As a bakery we are not yet making money and Ive had to fight an industry that has brainwashed people into thinking that food can be cheap.

I know its generally not politically correct to go so hard on this organic way of eating because people will argue that it is elitist, privileged and only a certain percentage can afford organic food.

But when I had the bakery in Hackney we had loads of customers who were on the breadline buying our bread because they fundamentally understood the importance of organic, wholegrain food in their diet.

This month ODonoghue launches her 48-hour soaked wholegrain Chia Teff Loaf, aka the magic poo bread, to the Irish market on a nationwide delivery service.

She also runs baking classes at her school house, Teach Scoile, in Westport to educate people on the benefits of teff.

As a baker, she separates bread makers into two camps.

There are those who nourish, and there are those who feed, she says.

And Ive always wanted to nourish.

When I had that epiphany at 10 years of age I knew that this brand will be more of a vocation than a business.

What Im doing here is a vocation about preventative medicine to give every single person suffering with IBS access to food and education that works.

Link:
Meet the Cork-born bread activist who has Goldie Hawn buying her loaves - Irish Examiner

Read More...

Pfizer says pill cuts risk of severe Covid by 89% – RTE.ie

Sunday, November 7th, 2021

A trial of Pfizer's experimental antiviral pill for Covid-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalisation or death for adults at risk of developing severe disease, the company said.

The results appear to surpass those seen with Merck's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalised for Covid-19 patients also at high risk of serious illness.

Full trial data is not yet available from either company.

Professor Luke O'Neill said the new drug is "very significant" because the manufacturer got 89% efficacy in their trial.

The Trinity immunologist added: "What that means is 9 out of 10 people wouldn't end up in hospital with Covid. If that turns out to be true once it's launched that would be remarkable.

He said this disease is an emergency and Pfizer is applying for emergency use in the United States with the FDA and also with the European Medicines Agency (EMA).

"Those agencies will look very closely at the data and the safety and they will be really under pressure now approve these drugs because an antiviral is a great extra weapon to use against this virus," Prof O'Neill said.

Separately, the Tnaiste has said a new antiviral oral pill for Covid will be a "very valuable weapon" and he hopes it can be approved by the EMA "quite soon".

Yesterday, the UK medicines regulator became the first to approve the drug 'Molnupiravir', for people who have had a positive Covid test and have at least one risk factor for developing severe illness, such as obesity, being over the age of 60, diabetes or heart disease, something Leo Varadkar said was "really encouraging".

Mr Varadkar said: "Once you are diagnosed you can take this tablet and it reduces by up to half the chances of you needing to be hospitalised, so that can really make a big difference.

"I hope the EMA will approve that quite soon, because you can never deal with a virus through vaccination alone, you need therapeutics too and you need preventative medicine.

"This is going to give us an extra weapon in our armoury and a very valuable weapon too," he added.

Pfizer will now submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the US Food and Drug Administration as part of the emergency use application it opened in October.

The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.

A spokesperson from Pfizer in Ireland said that the company's plant in Ringaskiddy "will support the global manufacturing and supply" of the drug, if it is given approval.

He said: "Pfizer has begun investing prior to regulatory authorisation in the manufacture of our potential Covid-19 oral antiviral candidate to help bring this potential treatment to patients as soon as possible.

"Pfizer's site in Ringaskiddy has a successful history of contributing to our manufacturing efforts."

We need your consent to load this rte-player contentWe use rte-player to manage extra content that can set cookies on your device and collect data about your activity. Please review their details and accept them to load the content.Manage Preferences

The planned analysis of 1,219 patients in Pfizer's study looked at hospitalisations or deaths among people diagnosed with mild to moderate Covid-19 with at least one risk factor for developing severe disease, such as obesity or older age.

It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalised and none had died by 28 days after treatment.

That compared with a hospitalisation rate of 7% for placebo patients. There were also seven deaths in the placebo group.

Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalised, compared with 6.7% for the placebo group, which included ten deaths.

Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.

"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective," said Annaliesa Anderson, head of the Pfizer programme.

The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.

"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients' lives, reduce the severity of Covid-19 infections, and eliminate up to nine out of ten hospitalisations," said Pfizer Chief Executive Albert Bourla.

Infectious disease experts stress that preventing Covid-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.

Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.

Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus.

Merck has already sold millions of courses of the treatment, which was approved this week by UK regulators, to the US, the UK and others.

Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.

Pfizer is also studying whether its pill could be used by people without risk factors for serious Covid-19 as well as to prevent coronavirus infection in people exposed to the virus.

Read more:
Pfizer says pill cuts risk of severe Covid by 89% - RTE.ie

Read More...

The roots of ivermectin mania: How South America incubated a fake-medicine craze that took the US by storm – Yahoo News

Sunday, November 7th, 2021

A supporter of President of Brazil Jair Bolsonaro waves a box of ivermectin at a pro-government demonstration in Brasilia in May 2021. Andressa Anholete/Getty Images

The popularity of unproven anti-parasitic drug ivermectin as a COVID-19 treatment is surging.

Its use has roots in South America, where it was hyped by populist leaders citing debunked research.

"Nobody paid attention... now we see the same" in the US, a Peruvian official told Insider.

In May 2020, when the coronavirus was sweeping the South American nation of Peru, Dr. Patricia Garcia of the country's health ministry began receiving disturbing reports from the country's hospitals.

They detailed injuries not caused by COVID-19, but a drug people thought would help them: the anti-parasitic substance ivermectin.

"The kind of things they were telling was people that were coming with severe gastritis [stomach inflammation], and also pancreatitis, because they were taking the ivermectin in desperation," Garcia told Insider.

As the coronavirus continued to spread, people's faith in ivermectin as a way out of the crisis grew more fervent, said Garcia.

It would be almost a year before ivermectin would become widely discussed in the US, as a subset of Americans began to insist on receiving it.

The US demand for ivermectin surged as vaccination - the most effective COVID countermeasure - became increasingly politicized. Doctors strongly advise against taking it but, as of October 16, more than two-dozen lawsuits had been filed around the US from people demanding access to it.

"History is repeating," said Garcia. "Nobody paid attention about what was happening in Latin America and now we see the same situation."

A municipal worker sprays disinfectant past a street vendor at a market in Puno, Peru, near the border with Bolivia, on June 10, 2020. CARLOS MAMANI/AFP via Getty Images

In the Peru of May 2020, there were no vaccines, and ivermectin's rise was being driven by hope and desperation.

Pharmacies fast ran out of pills as thousands sought to obtain it, and a lucrative ivermectin black market emerged, as local media reported at the time.

Adherents recommended both that healthy people take ivermectin as a preventative, and that it be used to treat COVID-19 after infection.

Story continues

Many resorted to a stronger version of the drug, normally used to deworm horses. That form is taken by injection, and people who took it were left with serious skin lesions, said Garcia.

As the fervor spread, evangelical groups based in southern Peru injected 5,000 people from indigenous communities with the drug.

In some cities, including the capital, Lima, public health officials distributed the stronger, dangerous form of the drug to whole neighborhoods.

The belief that ivermectin could work against COVID-19 is almost as old as the pandemic, predating vaccines and even proper testing.

Almost two years later, there is still no conclusive evidence that ivermectin is effective against COVID-19, and it has been repeatedly debunked, including by the FDA in September.

It said that taking large doses of any kind of ivermectin is dangerous, and that humans should never take drugs intended for treating animals.

Carlos Chaccour, a researcher at the Barcelona Institute for Global Health, pointed to an obscure research paper in early 2020 which appeared to answer the desperate desire for a workable treatment.

The paper drew on data from Surgisphere Corporation, a small research group in Chicago, which published it in April 2020 seeing to establish a link between taking ivermectin and surviving COVID-19.

A pharmacist in Santa Cruz, Bolivia, with doses of ivermectin. Rodrigo Urzagasti/picture alliance via Getty Images

The researchers, who also touted hydroxychloroquine, said the paper's basis was data from thousands of hospitals around the world. Their research was published by top-tier medical journals including The Lancet and The New England Medical Journal.

But doubts soon emerged the authenticity of Surgisphere's data, the credentials of its team, and the methodology they used.

The Lancet and The New England Medical Journal retracted the study after a backlash from the scientific community and an investigation by The Guardian. But by then, said Chaccour, the damage was done.

In summer 2020, government officials in Peru, Bolivia, and Guatemala made ivermectin part of their COVID-19 strategies, often citing the retracted study as evidence.

Chaccour told Insider that the drug was embraced so readily because it seemed to present a simple solution, was relatively cheap, and was already widely used in the region.

He noted that a danger of the drug - perhaps worse than its adverse effects - was that people who believed it to be effective against COVID-19 were more likely to ignore actions that actually work.

"One of the risks of ivermectin is not just the safety, but the hazard of people not using masks or not getting vaccines or not doing social distancing because they think they are protected," he said.

As a second wave of the coronavirus hit South America in the latter half of 2020, ivermectin became more popular still. The city of Cali in Colombia handed it out to all of its COVID patients in late July. Weeks later the state of Chiapas in Mexico followed suit.

In Brazil, South America's most-populous country, the drug was endorsed by the country's populist president, Jair Bolsonaro, and by his allies at a regional and national level.

But it wasn't just politicians. They were riding a wave of social-media misinformation that was still spreading. In groups on Facebook and WhatsApp, misinformation about ivermectin was being shared by millions, experts told Insider.

Among its influential promoters was COMUSAV, a group of renegade medics based in Bolivia, whose core product was a kind of industrial bleach promoted as a miracle cure for a vast array of ailments that included COVID-19.

They pushed ivermectin to their followers across the continent on their Facebook pages, which had tens of thousands of followers.

(Many of the group's pages were removed following an investigation by Insider in March 2021.)

A data analyst, Juan Chamie, was among those who helped to bring the enthusiasm for ivermectin from the populists of South America to their equivalents in the US, experts told Insider.

Chamie claimed to have data showing lower COVID-19 mortality in parts of South America where public health authorities approved ivermectin.

But Chaccour and data scientist Joe Brew have said his analyses are misleading, and ignore other factors that could explain the differences.

"Just because things are associated does not necessarily mean that one thing causes the other," they said.

That hasn't stopped Chamie's analyses being shared widely, until his account was suspended by Twitter.

Among those taking note was Laura Ingraham, primetime host of Fox News' show "The Ingraham Angle."

In December 2020 Ingraham posted a graph of data attributed to Chamie to her 3.8 million followers.

It purported to show a reduction in COVID-19 cases, comparing areas of Chiapas, Mexico, where officials did and did not distribute ivermectin.

Chaccour said that, as with Chamie's other claims, the decrease could be coincidental or due to other factors.

Ingraham already had a history of promoting ivermectin. As far back as March 2020, Ingraham had tweeted about the Surgisphere research that was later debunked.

Chaccour believes that Ingraham's advocacy was a tipping point for ivermectin in the US.

Progressive campaign group Media Matters noted that Ingraham's enthusiasm extended to her widely-viewed Fox News show.

In two episodes in December 2020, Ingraham claimed that medical authorities were conspiring to suppress the substance and ignoring evidence of its effectiveness. Andrew Lawrence, a Media Matters staffer, told Insider that Ingraham was "definitely the leader" among network hosts promoting the substance.

A Fox News spokesperson said in Ingraham's defense that she never explicitly told viewers to take the drug.

In comments to The Washington Post, Ingraham criticized attempts to "silence" scientists with unorthodox messages. "Just like the scientific consensus, the medical consensus is evolving. It changes," she sad.

Chamie also formed contacts with the Front Line Critical Care Alliance (FLCCA), a group of US medics who were influential in pushing ivermectin in the US, as detailed in a September investigation by Insider's Hilary Brueck.

Chamie describes himself as a senior data analyst for FLCCA on his LinkedIn page, and the group cites his research on its website.

The group has been instrumental in brokering ties between the pro-ivermectin movement and Republican lawmakers who promoted the drug.

Last December, Dr Pierre Kory, a member of the group, testified before the US Senate about ivermectin in what one critic, Brown University dean Dr. Ashish Jha, described in The New York Times as a "misinformation super-spreader event."

In a statement to Insider, the FLCCC defended its position on ivermectin, forwarding Insider a list of studies based on anecdotal evidence suggesting that ivermectin may be effective in reducing COVID-19 deaths. These studies are not considered conclusive by experts.

The group did not respond to questions regarding Chamie's research, and Chamie himself did not respond to requests for comment from Insider.

As proponents in the US clamored for wider use of ivermectin, in South America disillusioned officials were reversing their position.

In February Peru removed ivermectin from its COVID treatment protocol altogether because of the absence of evidence that it worked.

"It's incredible for me that we, a whole region, already went through this terrible situation in which lots of people have died," Garcia, the Peruvian official, told Insider.

"They were taking ivermectin because it was known to us, so it was easy for us. And it didn't work."

Read the original article on Business Insider

Read the rest here:
The roots of ivermectin mania: How South America incubated a fake-medicine craze that took the US by storm - Yahoo News

Read More...

The pandemic exposed Montreal’s inequalities, and residents say it’s time to tackle root causes – CBC.ca

Sunday, November 7th, 2021

What was long suspected was quietly confirmed last month: Montrealers who live in the city's poorest neighbourhoods were more likely to die from COVID-19 at the height of the pandemic.

Now community organizers and experts are turning to how to best address the underlying issues that contributed to the disproportionate impact of the pandemic on the city's lower income, more racialized neighbourhoods.

"It really sheds light on the fact that social inequalities here since long before the pandemic are still here and need to be addressed," said Vronique Nadeau-Grenier, the lead researcher on the study conducted by Montreal public health.

The study, released Oct. 13, found a clear correlation between a neighbourhood's material advantages a metric which includes education and income levels and COVID-19 mortality rates.

The public health agency recommended a multitude of changes to address the underlying disparity in the city.

Some of them can be addressed by the City of Montreal, which is set to hold its municipal electionNov. 6 and 7, and others are more complex issues that involve several levels of government.

They include an increase in pay for low-wage workers and the fostering of more stable workplaces (movement between healthcare workplaces was an early contributor to the spread of COVID-19 in Quebec), increase to the availability of affordable quality housing and improved access to social and health services in disadvantaged areas.

The findings underscore those laid out in a CBC News analysis last year after the city's first wave.

Vulnerable populations, such as people living in low-income households, with precarious employment and in underprivileged neighbourhoods, represented both the most cases and deaths linked to COVID-19.

On average, underprivileged neighbourhoods had twice the number of cases and deaths than more affluent ones.

Marjorie Villefranche, the head of Maison d'Haiti, a community organization in Montral-Nord, said the numbers confirm what she has been saying for more than a year.

"We kept saying it and no one was listening," she said. Villefranche said the pandemic highlighted the lack of services in the area.

Montral-Nord, the report found, has the highest mortality rate of any sector: three times higher than some parts of the West Island.

The borough also has the highest per capita case count in the city: 12,079 cases per 100,000 people, as of Oct. 28.

Parole d'excluEs and Hoodstock, both of which have been calling for more research on pandemic impacts, released their own survey of residents. The report found a gap in health and mental health services, and the need for improved communication with residents.

"What all this highlights is that there needs to be a massive investment for community-based organizations in these poorer neighbourhoods that would lead to better access to health care and social services," said Olivier Bonnet, head of Parole d'excluEs.

Mabel Carabali,an assistant professor in the department of social and preventative medicine at University of Montreal, who holds adjunct position at the Dalla Lana School of Public Health at the University of Toronto, said such dynamics are visible in many cities.

She said the underlying issues have been "neglected for too long" and they need to be put under the microscope long after the municipal election cycle.

In Montreal, the disparity played out during the first three waves of COVID-19. By the summer of 2021, according to the report, the disparity had subsided with the spread of COVID-19 on the decline.

Nicholas King, a professor at McGill University who conducts research in public health ethics and policy, said it would be useful to dig deeper into the causes of that levelling off.

"That may give us some clues for us intervening in the future to try to reduce inequalities in health," he said.

In the meantime, he said the government should commit to more quickly and consistently reporting on health and social inequality.

King touted community groups in the province for stepping up and into the breach by producing the data themselves when they noticed the lag.

He said while experts and governments rely on public health authorities to understand what should be done next, community groups can benefit from the data themselves.

"Often some of the most effective interventions against inequalities are bottom up."

Originally posted here:
The pandemic exposed Montreal's inequalities, and residents say it's time to tackle root causes - CBC.ca

Read More...

Prior poor mental health linked with higher rates of COVID- study – The Jerusalem Post

Sunday, November 7th, 2021

Several studies have shown that the pandemic took a devastating toll on peoples mental health and impacted other psychiatric conditions, but a novel study looked at things from a different perspective.The investigation, conducted by Yale School of Public Health and published in the American Journal of Preventative Medicine, looked at US nationwide levels of mental health to establish that those with poor mental health prior to the pandemic have a greater likelihood of developing a COVID-19 infection.

Researchers used aggregated data from a survey conducted across 2,839 counties to conclude that between 2010 and 2019, a total of 2,172 counties (77%) experienced significant increases in the average number of poor mental health days, including depression, stress and problems with emotions.

cnxps.cmd.push(function () { cnxps({ playerId: '36af7c51-0caf-4741-9824-2c941fc6c17b' }).render('4c4d856e0e6f4e3d808bbc1715e132f6'); });

Further research revealed that more days of poor mental health in 2019 had a robust association with the rate of COVID-19 infections in 2020, leading researchers to believe that the pandemic did not cause new mental health problems, but rather revealed previously ignored issues.

Analysis revealed that poorer mental health days and COVID rates were driven by a few states-- Arizona, Montana, and Nevada.

Lead investigator Yusuf Ransome expressed hope that the study will encourage conversation about the urgency of mental health care.

We call for policies that strengthen surveillance systems to better capture a range of mental health outcomes in the population, address social inequalities that give rise to poor mental health, and [increase] funding to create, sustain and equitably distribute mental health resources, including wellness care centers across US communities," he said.

Ransome added that the idea for the study was inspired by the height of the pandemic.

"Only a handful of studies examining small fragments of the population had considered the possibility that poor mental health could be contributing to a higher burden of infection rather than vice versa," he said. "We wanted to examine whether these relationships also existed in the general population, address the lack of studies with an ecological-level focus, and produce evidence to strengthen calls for interventions.

Continue reading here:
Prior poor mental health linked with higher rates of COVID- study - The Jerusalem Post

Read More...

Humans and Hardware: How Special Operations Can Pioneer Wearable Technology – War on the Rocks

Sunday, November 7th, 2021

In 2009, the U.S. Special Operations Command announced that Humans are more important than hardware. But with wearables revolutionizing sports medicine and athletics, the distinction between humans and hardware is less relevant than ever. This means that investing in wearable technology for special operations forces is now the best way to put humans first.

What might this look like? With a small population of elite warfighters in high-stress environments, Special Operations Command can lead the force in determining which wearable devices are worth the investment. The Preservation of the Force and Family program, which is already in place to improve the holistic health of special operations forces, can spearhead efforts to distribute, monitor, test, and best utilize wearables for the entire military.

A Wearable Revolution

In the last two decades, sports medicine and sports science have advanced dramatically. Athletes are now bigger, faster, and stronger due, in part, to advancements in technologies that allow them to train smarter. A critical facet of this revolution is wearable technology that offers athletes immediate and continuous feedback on an increasing number of health and performance metrics. The wearable trend started with simple Global Positioning System-enabled devices measuring steps taken in a day and heart-rate monitors allowing users to train in specific heart-rate zones. However, wearable technology is now quickly outpacing older, more expensive, and more invasive technologies. New Apple Watches, for example, allow users to bypass hospital visits by serving as both an electrocardiogram to monitor heart health and a pulse oximeter to measure blood oxygen levels in 10 seconds. Wearables rapid development is providing valuable new tools for physical therapists and healthcare professionals and eliciting optimism about the future of individualized self-care.

This revolution hasnt gone unnoticed by the Department of Defense, which is testing wearables across different military branches. The U.S. Air Force recently began using the Oura Ring, a technology worn on your finger, to more accurately determine pilots flight readiness in the morning based on their overall sleep score. Previously, pilots flight readiness was determined by hours in bed rather than the quality of sleep. However, Oura Rings offer the ability to both measure sleep quality and potentially improve sleep, making pilots fitter to fly. Additionally, the U.S. Navy regularly tests various wearable devices at the Naval Postgraduate School Human and Systems Integration laboratory to study and improve crew rest, while the U.S. Army tests wearables to study soldiers resiliency in harsh winter conditions. As wearable technology continues to progress, so do the applications and opportunities to improve service members sleep, fitness, and overall health.

Wearables Potential in Special Operations

In 2012, Special Operations Command adopted the Preservation of the Force and Family strategy. The goal was to optimize and sustain mission readiness, longevity, and performance, thereby maximizing the estimated $1.5 million investment that the military makes in each member of special operations. The strategy seeks to provide precise preventative interventions and emphasisizes holistic health across five domains: physical, cognitive, psychological, social and family, and spiritual.

Wearable technology is already improving individual physical fitness and should be a critical component in enhancing operator health across every all of these domains. Wearables currently track a host of physical and biological metrics and use algorithms to generate useful approximations of additional metrics, including sleep quality, readiness, and stress. Many wearable interfaces offer coaching to nudge users towards healthier behaviors. Leading wearables, including the Oura Ring, Apple Watch, and Whoop Strap, offer nuanced sleep and activity coaching based on users unique metrics and trends. Put simply, wearables can tell you when you are overworked and need a break.

In an organization like Special Operations Command, which demands long hours under highly stressful conditions, having a tool that provides an objective measurement of readiness is uniquely valuable. Operators are specially selected and trained for resilience to adverse physical and mental conditions. Constant adaptation to a changing environment, however, comes at a cost. But this advantageous adaptation can produce allostatic load, leading to chronic physical maladies including pain, fatigue, and compromised immunity. Reduction of allostatic load first requires identification of increased stress. Enter wearables. Wearables can provide feedback on a host of biological metrics correlated with stress, including heart-rate variability, resting heart rate, and sleep quality. This makes it possible to identify chronic physiological stress, implement nuanced interventions, and prevent the difficulties associated with allostatic overload.

Wearables can also bring benefits in the cognitive and psychological domains. The Oura Ring encourages users to monitor body signals through practices such as guided mindfulness and breathing protocols. As shown by ongoing studies at Texas A&M, mindfulness meditations and associated breathing exercises can reduce stress and improve mental health. This can be particularly useful to special operations forces in reducing combat mental illness. Paired with blast gauge data or baseline cognitive tests such as the Automated Neuropsychological Assessment Metrics, wearables may also allow the early identification and treatment of traumatic brain injury.

Mitigating Concerns

In a profession where chronic stress is so abundant that it produced the term operator syndrome, why are wearable technologies not already commonplace? For one thing, there isnt a one-size-fits-all wearable. While one wearable specializes in sleep, for example, it may not be as effective at measuring physical activity. Concerns over operational security also dampen wearable enthusiasm in the Defence Department. And for good reasons in 2018, the fitness and location tracking application Strava infamously illuminated the location of multiple overseas military bases. Similarly, privacy risks regarding collected data can cause hesitation in an increasingly connected and data-driven world. Data security and patient confidentiality are paramount concerns with aggregated health information collected from wearables, and have legal implications under the Health Insurance Portability and Accountability Act. While data is routinely stripped of identifiers, including names and addresses, it can become re-identifiable when correlated with other datasets.

Special Operations Command has an important role to play in helping to address these security and privacy concerns. Letting the Preservation of the Force and Family program lead the development of wearables can help by removing military commanders from the loop, preventing mandatory use and giving participants the power of consent. Personnel associated with this program are also trained and certified to handle protected health information, reducing the risk of a Health Insurance Portability and Accountability Act violation and relieving military commanders of such a burden. Assigning random user identifications can help to avoid the disclosure of personal data. Preservation of the Force and Family personnel can further prevent the re-identification of anonymous users by isolating the wearables data, thereby preventing their merging with larger military data sets.

While there are simple ways to mitigate the known concerns over wearables, there will always be risks, especially with the early adoption of technology. These risks should be explored, preferably in a small and competent population, to best identify and understand wearables capabilities and limitations. Implementation and open dialogue will enable the force to exploit wearables significant potential to improve holistic health.

Wearables Are Coming!

In any technological revolution, there will be resistance to adopting new technology, especially in large organizations like Special Operations Command. Nevertheless, wearable technology has taken the world by storm. Large corporations have adopted wearables into healthcare policies, and wearable tech is an $81.5 billion industry. With a smaller population that is often presented with high chronic stress, Special Operations Command has the opportunity to lead the U.S. military in the use of wearable technology. By leveraging the recent revolution in wearables, programs such as Preservation of the Force and Family can bring humans and hardware together in the safest and smartest way possible.

Maj. Kevin Butler and Maj. Frank Foss are Army Special Forces officers currently pursuing a masters in Defense Analysis at the Naval Postgraduate School. Between them, they have over a dozen combat and operational deployments to the Central Command and Southern Command.

Disclaimer: The views expressed in this article are the views of the authors alone. They do not reflect the official position of the Naval Postgraduate School, the U.S. Army, the Department of Defense, or any other entity within the U.S. government and the authors are not authorized to provide any official position of these entities.

Image: U.S. Army (Photo by Sgt. Apolonia Gaspar)

Originally posted here:
Humans and Hardware: How Special Operations Can Pioneer Wearable Technology - War on the Rocks

Read More...

Halting COVID-19 in its tracks – UBC Faculty of Medicine

Sunday, November 7th, 2021

Nearly two years into the global pandemic, there remain a handful of approved therapies to treat COVID-19.

Dr. Dermot Kelleher

And with emerging variants threatening the effectiveness of existing vaccines, there is an ever-pressing need to find new treatment approaches to fight the disease.

At UBCs faculty of medicine, researchers Dr. Dermot Kelleher and Dr. Shane Duggan are tackling this challenge head on, redirecting elements of their groundbreaking research on esophageal disease to develop a novel aerosol treatment for COVID-19.

The global effort to intervene in the spread and severity of COVID-19 has produced several effective vaccines, but there is still a pressing need for new treatments for people who contract the virus and to safeguard the health and well-being of those who are most vulnerable to disease transmission, says Dr. Kelleher, dean of the faculty of medicine and vice-president, health at UBC.

The proposed therapyset to be delivered to the lungs as an aerosol using a handheld nebulizerwould be designed to stop the virus from replicating, halting the progression of COVID-19 in an effort to reduce harmful health effects and save lives.

The global effort to intervene in the spread and severity of COVID-19 has produced several effective vaccines, but there is still a pressing need for new treatments for people who contract the virus and to safeguard the health and well-being of those who are most vulnerable to disease transmission. Dr. Dermot Kelleher

The researchers are hopeful that the treatment could help reduce hospitalizations and one day delay or even eliminate the need for mechanical ventilators for patients who contract the disease. They also see great potential for the therapy to be used as a prophylactic, or preventative treatment, capable of temporarily reducing the risk of infection and protecting healthcare workers on the frontlines as well as others at increased risk.

This is an excellent example of the world-class biomedical research taking place at UBCs Academy of Translational Medicine (ATM), says Dr. Poul Sorensen, director of the ATM. The ATM is a powerful innovation hub dedicated to accelerating the translation of scientific discoveries into clinical practice, rapidly solving some of lifes most pressing health challengesfrom COVID-19 and cancer to diabetes and dementiabringing real and lasting hope to everyone.

This research also nicely complements the groundbreaking work underway in Dr. Josef Penningers laboratory at UBCs Life Sciences Institute (LSI), where they are examining the use of an inhalable form of the ACE2 protein to bind the virus and halt COVID-19, adds Dr. Sorensen.

Within UBCs Life Sciences Institutethe largest biomedical research institute of its kind in Canadathe research team is already hard at work in the Kelleher lab, using cutting-edge technology to identify and design molecules to target SARS-CoV-2, the virus that causes COVID-19.

Once inhaled, these specialized molecules, known as GapmeRs, would stick to the virus and degrade its DNA, thereby preventing the virus from replicating further, while limiting infection and further transmission.

Dr. Shane Duggan

Ultimately, by embracing GapmeR technology and a simple delivery system, such as a nebulizer that doesnt rely on specialized equipment, the researchers believe their approach could represent a much more cost-effective means of combatting COVID-19 and saving lives around the worldincluding harder-to-reach regions.

Its our duty as researchers to use every tool in our toolkit to advance knowledge of COVID-19 and rapidly rethink our current treatment approaches to make a direct impact on patient lives both here in Canada and around the world. Dr. Shane Duggan

Treatments based on GapmeR technology are relatively easy to manufacture and require no specialized storage or transport, which make them ideal for distributing to vulnerable communities in need, says Dr. Duggan, a research associate in the division of gastroenterology.

In the coming months, the research team, which has recently grown to include two postdoctoral fellows with expertise in virology, will begin rapidly identifying molecular candidates with the highest chance of success. Following this, they will begin working with the live virus.

In an effort to accelerate the development of the new treatment, the UBC research team will also collaborate with a group of scientists with expertise in GapmeR technologies led by Dr. Navin Verma at the Lee Kong Chian School of Medicine, Nanyang Technological University in Singapore. Through this international partnership, the team hopes to bolster the studies needed to turn their research into a clinical reality, ultimately expediting the path from bench to bedside.

Beyond COVID-19, the treatment approach has the potential to be rapidly mobilized and tailored to fight future viral outbreaksand could one day be used to help tackle other diseases, including some forms of cancer.

The beauty behind this technology is that it holds tremendous potential because its readily translatable and scalable, says Dr. Duggan.

But right now, with COVID-19 forecasted to remain for the foreseeable future, the research team remains focused on the current pandemic and accelerating an aerosol treatment to save lives.

COVID-19 has already claimed the lives of millions and impacted millions more around the world, says Dr. Duggan, who, after losing a family member to a combination of COVID-19 and liver dysfunction last year, understands the high stakes at hand more than most.

Its our duty as researchers to use every tool in our toolkit to advance knowledge of COVID-19 and rapidly rethink our current treatment approaches to make a direct impact on patient lives both here in Canada and around the world.

At UBC, this is hope, accelerated.

Read the original post:
Halting COVID-19 in its tracks - UBC Faculty of Medicine

Read More...

Preventive Medicine Residency Programs | ACPM

Friday, October 15th, 2021

Preventive medicine is a specialty that bridges clinical practice and public health. Specialists work in diverse settings and tap into a broad skill set to prevent disease and promote the health of individuals, communities and populations.

Physicians completing a preventive medicine residency gain a breadth of skills that opens many potential career paths in population health system management, public health and epidemiology, clinical care, health informatics, public health policy development and much more. Preventive medicine physicians work in a variety of settings including state and local health departments, Fortune 100 companies, health systems and all levels of government.

Click HERE to download a full list of Preventive Medicine Residency Programs.

Completion of residency training in preventive medicine is an essential step to become certified in one or more of the preventive medicine specialty areas: Public Health and General Preventive Medicine, Occupational Medicine, and Aerospace Medicine.

There are currently 72accredited preventive medicine residency training programs in the United States. Programs are administered by schools of medicine, schools of public health, state or local health departments, or in federal government agencies or branches of the uniformed services. They take an individualized approach to training, with approximately 350 residents in training every year.

Residency program accreditation and ongoing compliance reviews are performed by the Preventive Medicine Residency Review Committee of the Accreditation Council for Graduate Medical Education (ACGME).

Prospective residents must contact their desired residency programs directly for information and application instructions. Program directors may connect residents with program match specialists who can provide additional information and guidance. Many programs participate in the Preventive Medicine Electronic Residency Application Service.

ACPM administers a voluntary standardized acceptance process for General Preventive Medicine and Public Health residency programs. This centralized service provides the participating programs with a uniform method of selecting residents. ACPM opens registration in October and application review begins the following January.

Prior to an appointment in a preventive medicine residency program, applicants must have successfully completed at least 12 months of clinical education in a residency program accredited by the ACGME, Royal College of Physicians and Surgeons of Canada, or the College of Family Physicians of Canada.

Experience must include at least 11 months of direct patient care, in both inpatient and outpatient settings, where residents developed competency in the following clinical skills:

In addition to the base skills related to clinical practice, preventive medicine residency programs feature competencies in the following areas:

Two-year training programs include didactics, clinical training, research, public health and other population-based experiences. The didactic training includes both residency-lead seminars, as well as the acquisition of a Master in Public Health or equivalent degree. Those residents entering with an appropriate degree can enhance their didactics with additional coursework. Whether through a Master in Public Health or other equivalent degree, all residents must complete graduate level courses in epidemiology, biostatistics, health services management and administration, environmental health and the behavioral aspects of health.

Practicum experiences can take place across the two years of the residency and include acquisition of skills in clinical and population prevention medicine. Examples of practicum experiences include appointments in: local, state and federal health departments; health maintenance organizations; peer review organizations; community and migrant health centers; occupational health clinics; industrial sites; regulatory agencies; NASA; OSHA; research settings and many more. Reference the Examples of Preventive Medicine Training Opportunities for a comprehensive listing.

Combined residency training is designed to lead to board certification in two medical specialties. Combined programs may reduce the overall length of required training by as much as one year. Residencies that offer combined training programs must maintain their accreditation status through each specialty Residency Review Committee.

The ABPM and the American Board of Internal Medicine have formal guidelines for a combined 4-year residency training program, which leads to board certification in both Preventive Medicine and Internal Medicine.

Several institutions also offer 4-year programs with combined training in preventive medicine and family medicine.

The preventive medicine Standardized Acceptance Process (SAP) is a service offered by ACPM to aid in matching prospective preventive medicine residents with available positions at residency programs across the country. The SAP helps to create homogeneity in residency program acceptance timetables, and ensures programs and candidates have adequate time to complete interviews and make and accept offers.Since 2018, nearly three quarters of all General Preventive Medicine and Public Health residency programs have participated in the SAP match.

SAP policy information, program guidelinesand resources for 2022 will be posted soon.

October - November - Programs Register for the SAP

October- January, 2022 - Applicants Register for the SAP

November 12 - Program InformationalSession

November 19 - Applicant Informational Session

January 24 - 28,2022- Applicants submit ranked lists

February 1- 4,2022- Programs submit ranked lists

February 7 - 11, 2022 - SAP pairing period

Accordion toggle

Previous Slide

Next Slide

Accordion toggle

Previous Slide

Next Slide

Originally posted here:
Preventive Medicine Residency Programs | ACPM

Read More...

Preventive Medicine Services Reporting – AAPC Knowledge Center

Friday, October 15th, 2021

Preventive medicine services, or well visits, are evaluation and management (E/M) services provided to a patient without a chief complaint. The reason for the visit is not an illness or injury (or signs or symptoms of an illness or injury), but rather to evaluate the patients overall health, and to identify potential health problems before they manifest.The CPT code book includes a dedicated set of codes to describe preventive medicine services:

99381 Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; infant (age younger than 1 year)99382 early childhood (age 1 through 4 years)99383 late childhood (age 5 through 11 years)99384 adolescent (age 12 through 17 years)99385 18-39 years99386 40-64 years99387 65 years and older99391 Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year)99392 early childhood (age 1 through 4 years)99393 late childhood (age 5 through 11 years)99394 adolescent (age 12 through 17 years)99395 18-39 years99396 40-64 years99397 65 years and older

Code assignment is determined by the patients age (as detailed in the code descriptor), and whether the patient is new (99381-99387) or established (99391-99397). CPT applies the three year rule to determine new vs. established status. A patient is established if any physician in a group practice (or, more precisely, any physician of the same specialty billing under the same group number) has seen that patient for a face-to-face service within the past 36 months. The Decision Tree for New Vs Established Patients in the Evaluation and Management Services Guidelinesportion of the CPT code book can help you to select the appropriate patient status.Service Content Varies by Patient CircumstancePreventive medicine services must include a comprehensive history and examination, and age-appropriate anticipatory guidance. In the context of preventive medicine services 99381-99397, a comprehensive exam is not the comprehensive exam as defined by either the 1995 or 1997 Evaluation and Management Documentation Guidelines. Instead, the exam should reflect an appropriate assessment, given the specific patients age and sex. For example, the specifics of the exam will differ for a 4-yr-old male and a 22-year-old female.Services for a young child will assess physical growth (height, weight, head circumference) and developmental milestones such as speech, crawling, and sleeping habits. Anticipatory guidance may include use of car seats and other safety issues, introducing new foods, etc.An adolescent preventive service may include scoliosis screening, assessment of growth and development, and a review of immunizations. Anticipatory guidance may focus on developing positive health habits and self-care, including discussion of drug, alcohol, and tobacco use, and sexual activity.A comprehensive preventive visit for an adult female patient will include a gynecologic examination, Pap smear, and breast exam. An adult males exam would include an examination of the scrotum, testes, penis, and the prostate for older patients. Anticipatory guidance may focus on issues of health maintenance, such as alcohol and tobacco use, safe sex practices, nutrition, and exercise. The patients employment status and other family issues may be discussed. As patient age advances, cholesterol levels, blood sugar, and prostate-specific antigen(PSA) testing may become increasingly relevant.Diagnoses Must Support Preventive Nature of the VisitEvery billed service must be supported by an ICD-10-CM code(s) that describe the reason for that service. In the case of a well visitbecause there is no patient complaintyou should turn to so-called Z codes (Factors influencing health status and contact with health services). For example:

Z00.110 Health examination for newborn under 8 days oldZ00.111Health examination for newborn 8 to 28 days oldZ00.121 Encounter for routine child health examination with abnormal findingsZ00.129Encounter for routine child health examination without abnormal findingsZ00.00 Encounter for general adult medical examination without abnormal findingsZ00.01 Encounter for general adult medical examination with abnormal findingsZ01.411 Encounter for gynecological examination (general) (routine) with abnormal findingsZ01.419 Encounter for gynecological examination (general) (routine) without abnormal findings

You also should code for any abnormalities found, regardless of whether the finding requires an additionally reported service.Testing and Problem-Focused Testing Are SeparatePer CPT coding guidelines:If an abnormality is encountered or a preexisting problem is addressed in the process of performing this preventive medicine evaluation and management service, and if the problem or abnormality is significant enough to require additional work to perform the key components of a problem-oriented E/M service, then the appropriate Office/Outpatient code 99201-99215 should also be reported. Modifier 25 should be added to the office/outpatient code to indicate that a significant, separately identifiable evaluation and management service was provided on the same day as the preventive medicine service.To determine whether a problem requires significant work, consider whether the available documentation is sufficient to support each service (the preventive service and the problem-oriented service), separately.Additionally, per CPT coding guidelines, as supported by CPT Assistant(April 2005):

The codes in the preventive medicine services include the ordering of appropriate immunization(s) and laboratory or diagnostic procedures. The performance of immunization and ancillary studies involving laboratory, radiology, other procedures, or screening tests identified with a specific CPT code are reported separately.

Payer Coverage May VaryThe Affordable Care Act (ACA) requires insurers to cover recommended preventive services without any patient cost-sharing, but exact coverage and reporting requirements may vary from payer to payer. As CPT Assistant(April 2005) notes:

Codes 99381-99397 are used to report the preventive evaluation and management (E/M) of infants, children, adolescents, and adults. The extent and focus of the services will largely depend on the age of the patient. For example, E/M preventive services for a 28-year-old adult female may include a pelvic examination including obtaining a pap smear, breast examination, and blood pressure check. Counseling is provided regarding diet and exercise, substance use, and sexual activity.

Based upon this information, it is not be appropriate to separately report for a pelvic exam including obtaining of the pap smear, nor the breast exam as these services are considered part of a comprehensive preventive medicine E/M services.Although this reporting method reflects the intent of CPT coding guidelines, third-party payers may request that preventive medicine services be reported differently. Third-party payers should be contacted for their specific reporting guidelines.Authors Note:Although the CPT Assistantarticle cited pre-dates the ACA, the advice to contact your payers regarding their reporting requirements remains valid.Be aware, as well, that Medicare reporting requirements, as stipulated by the Centers for Medicare & Medicaid Services (CMS) often differ from CPT guidelines. For more information about Medicare Preventive Medicine Services and Screenings, visit the CMS website.

John Verhovshek, MA, CPC, is a contributing editor at AAPC. He has been covering medical coding and billing, healthcare policy, and the business of medicine since 1999. He is an alumnus of York College of Pennsylvania and Clemson University.

See the rest here:
Preventive Medicine Services Reporting - AAPC Knowledge Center

Read More...

Healthcare Conferences and Preventive Medicine Conferences …

Friday, October 15th, 2021

Scope & Importance

Vision

We work hard to improve the lives of our patients and their families by collaborating with the healthcare community. We offer clinical experience to both allied health professionals and patients.

We focus on the right to comprehensive, high-quality primary care for individuals and populations.

To provide the most safest, ethical, and effective medical care possible. Practice the safest, most ethical and effective medical care possible. Breakthrough research can lead to the discovery of new treatments and therapies. Promoting healthy and reducing health disparities. Educate and inspire faculty, healthcare developers, policy makers and leaders of the next generation. Build a philanthropic culture for patient care and research.

Mission

Our objective is to disseminate healthcare information and innovations that will guide in a new era of medicine.

Healthcare Market Forecast

Healthcare is one of those industries that has never seen ups and downs, particularly since technology has taken over its progress.Even throughout the pandemic, technology was important in advancing healthcare to a higher level.

In 2019, the global home healthcare market was valued at USD 281.8 billion, with a compound annual growth rate (CAGR) of 7.9% predicted from 2020 to 2027. Market growth is expected to be increased by global population ageing and rising patient preference for value-based healthcare. In 2019, the World Health Organization (WHO) estimated that 703 million people aged 65 and up lived in the world. By 2050, the number of elderly people is expected to increase to 1.5 billion. The ageing population necessitates more patient-centric healthcare services, which in turn raises demand for healthcare personnel and agencies, drive market growth.

Medicare is the largest single payer of home healthcare services in the United States. Medicare accounts for more than 40% of all home health care expenses.

Healthcare Market Overview in USA

The home healthcare market is divided into two components: equipment and services, wherein the services segment dominated the market with a share of 80% in 2019. The demand for home healthcare agencies is increasing as the world's population ages, resulting in better patient outcomes. Furthermore, the rising frequency of chronic diseases among the elderly is a prominent factor contributing to market growth.

In 2019, therapeutic devices dominated the equipment market. The growing number of patients with chronic or severe respiratory infections, urinary infections, or end-stage renal disease (ESRD) necessitates the use of innovative devices for treatment. Another important element driving the therapeutic equipment market is lower service rates for in-home healthcare when compared to hospitals or nursing homes. End-stage renal diseases (ESRD) affects roughly 750,000 persons in the United States each year, and 2 million patients worldwide, according to the University of California, San Francisco

The diagnostics equipment market is expected to develop at a healthy rate over the projected period, owing to the rising prevalence of diabetes and cardiovascular illnesses, both of which necessitate constant monitoring. Furthermore, increasing patient awareness of the screening process and technological advancements, such as the integration of microfluidics, sensors, the Internet of Things (IoT), smartphones, and wearables, provide point-of-care testing to patients and represent a significant opportunity for providing sensitive, low-cost, rapid, and connected diagnostics.

In 2019, North America dominated the home healthcare industry with a 42% share. In 2019, the United States had the greatest market share in North America, due to changing trends towards in-home healthcare from nursing homes, technology advancements, and the presence of modern medical infrastructure. In addition, the region's market is being driven by high patient awareness levels, rising healthcare expenses, and the deployment of a streamlined regulatory framework. Profits in the U.S. healthcare industry are expected to grow at a 5% annual rate through 2024, with medtech and healthcare IT experiencing the fastest growth. Profits in healthcare information technology are expected to rise from 14 billion US dollars in 2019 to 28 billion US dollars in 2024.

Healthcare Market Overview in Japan

Japan is the world's second-largest market for medical devices and healthcare. Japan is open to innovative and high-quality products and technologies, with nearly 45% of medical devices imported.

By nearly 180,000 medical facilities, including hospitals and clinics, Japan has the world's second largest healthcare market. In fiscal FY 2010, national medical expenditure was 37.4 trillion (approx 249 billion @150 = 1), a 3.9 percent increase over the previous year. This was a record-high in terms of both level and rate of growth, driven by the implementation of cutting-edge medical technologies as well as one of the world's fastest ageing populations. As a result of the ageing population, demand for assistive and care products has increased. However, the market is already crowded with a wide range of products, making it extremely difficult for new entrants lacking unique selling points.

The Japanese medical device market is also the world's second largest, valued at 2.4 trillion yen (approx. 16 billion) in 2011, with foreign manufacturers accounting for 44.4 percent of the products. Japan has long been known as a high-tech nation, but the market for medical devices is still heavily reliant on imports.

Healthcare Market Overview in Europe

Despite rising global trade tensions and a sluggish global economic outlook for 2020, the global healthcare market is expected to surpass $2 trillion in 2020. BREXIT is expected to have a significant impact on the United Kingdom, Europe's largest digital healthcare market.

In the forecast period of 2020 to 2027, the healthcare IT market is expected to grow. According to Data Bridge Market Research, the market will be worth USD 150.97 billion by 2027, growing at a CAGR of 15.62 percent during the forecast period.

The European healthcare market is expected to grow from approximately $2080 billion in 2016 to approximately $2125 billion in 2020. The European healthcare market is expected to exceed US$ 224 billion by 2022.

The European home healthcare market was worth USD 70.28 billion in 2019 and is expected to grow at an 8.37 percent CAGR to reach USD 105.04 billion by 2024.

In 2019, Germany had the highest market share in Europe, followed by France. This is mostly due to rising in-home healthcare spending in the country and rising demand for the skilled nursing workers to provide in-home care.

Healthcare Market Overview in Australia

The health care and social assistance industry is Australia's largest employer. This industry employed over 1.7 million people in 2020, with a projected increase to more than 1.9 million by 2024.

Occupations related to the HLT Health Training Package account for roughly one-third of the workforce in Health Care and Social Assistance. The occupations with the highest proportion of the workforce are Aged and Disabled Carers and Nursing Support and Personal Care Workers. Both are expected to grow significantly until 2024, with Aged and Disabled Carers growing by more than 25%. Other occupations in this sector are expected to grow to varying degrees as well. Welfare Support Workers, for example, are expected to grow by nearly 23%, Health and Welfare Services Managers by about 19%, and Complementary Health Therapists by about 15%.

Medical device industry overview: The medical device sector in Australia is mature, with a well-developed regulatory system. However, in the next years, it will be one of the slowest-growing economies in the South Pacific area. In 2016, the market was worth $4 billion, down from $5 billion in 2014. Due to Australia's sinking currency, market recovery will be delayed in 2019. Despite its low growth, Australia's ageing population, Federal Budget measures, and openness to adopt new technology should help to stabilise the market.

Australian market opportunities: Australia's healthcare business is sophisticated and open to innovative products. A wide range of medical gadgets, particularly those designed to treat and manage age-related disorders, are in high demand. Because the Australian market is pushed to cut prices, imported devices are frequently inventive and cost-effective. In addition, there is a growing demand for gadgets that help people with disabilities and chronic pain, as well as those that help them recover faster. The Australian market is highly accessible from a regulatory aspect for items that already have CE Marking.

Healthcare Market Overview in Middle East

Healthcare prospects are expanding across the Middle East. According to a recent analysis by the US-UAE Business Council, healthcare spending in the UAE is forecast to rise from $17 billion in 2017 to $21.3 billion by 2021, with a CAGR of 8.5 percent predicted between 2018 and 2023 in the UAE Healthcare Sector Outlook 2023 report.

Aging populations, longer life expectancies, and sedentary lifestyles, all of which contribute to an increase in obesity, cancer, and diabetes, are driving demand growth. New modes of care and out-of-hospital services are emerging as a result of an emphasis on prevention and well-being rather than simply treating patients. Saudi Arabia, for example, is developing a new healthcare system that includes primary, community, and secondary care.

Simultaneously, labour challenges, such as a lack of competent clinical staff and a strong reliance on expatriates, are pushing demand for technology such as digital health, artificial intelligence, and robots to fill the gap. By 2025, the region's medical technology market is estimated to be worth $31.6 billion.

The size of the Middle East and Africa Home Healthcare Market was worth USD 21.62 billion in 2020 and estimated to be growing at a CAGR of 9.30%, to reach USD 33.32 billion by 2025 during the forecast period.

These countries are expected to have a market size of USD 102 billion in 2024 with a CAGR value of 9.2% during the forecast period. Healthcare is the fastest-growing sector in the UAE, accounting for 79% of the market.

Healthcare Market Overview in APAC

The size of the home Healthcare Market in the Asia Pacific was worth USD 43.25 billion in 2020 and estimated to be growing at a CAGR of 12.56% to each USD 78.14 billion by 2025.

Home Healthcare Market Report Scope

Report Attribute

Details

Market size value in 2020

USD 303.6 billion in 2020

Revenue forecast in 2027

USD 515.6 billion

Growth Rate

CAGR of 7.9% from 2020 to 2027

Max Seats15 seats

Speaker Time20 mins

Go here to read the rest:
Healthcare Conferences and Preventive Medicine Conferences ...

Read More...

Page 7«..6789..2030..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick